| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 7 | 2024 | 415 | 2.630 |
Why?
|
| Nanoparticles | 8 | 2025 | 460 | 2.300 |
Why?
|
| Prostatic Neoplasms | 12 | 2020 | 1092 | 1.750 |
Why?
|
| Neoplasms | 6 | 2022 | 1377 | 1.440 |
Why?
|
| Immunotherapy | 2 | 2024 | 144 | 1.340 |
Why?
|
| Cell Movement | 13 | 2020 | 655 | 1.300 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 1019 | 1.240 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2023 | 307 | 1.230 |
Why?
|
| Plant Extracts | 4 | 2021 | 302 | 1.230 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2014 | 47 | 1.110 |
Why?
|
| Drug Delivery Systems | 4 | 2022 | 277 | 1.080 |
Why?
|
| Chemokines | 2 | 2022 | 96 | 1.020 |
Why?
|
| Taxoids | 2 | 2017 | 50 | 1.010 |
Why?
|
| Receptors, Chemokine | 5 | 2016 | 72 | 0.990 |
Why?
|
| Nanotechnology | 3 | 2024 | 176 | 0.950 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 220 | 0.920 |
Why?
|
| Cell Proliferation | 9 | 2020 | 1455 | 0.920 |
Why?
|
| Chemokine CCL5 | 3 | 2018 | 41 | 0.920 |
Why?
|
| Streptococcus pneumoniae | 4 | 2014 | 34 | 0.910 |
Why?
|
| Apoptosis | 11 | 2023 | 1568 | 0.880 |
Why?
|
| Cell Line, Tumor | 18 | 2023 | 2676 | 0.870 |
Why?
|
| Anti-Bacterial Agents | 5 | 2013 | 432 | 0.840 |
Why?
|
| Cytokines | 6 | 2022 | 678 | 0.810 |
Why?
|
| Quinazolinones | 3 | 2008 | 10 | 0.800 |
Why?
|
| Bacterial Proteins | 4 | 2014 | 595 | 0.790 |
Why?
|
| Humans | 53 | 2025 | 43102 | 0.780 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2024 | 968 | 0.770 |
Why?
|
| Chemokines, CC | 6 | 2014 | 55 | 0.740 |
Why?
|
| Cachexia | 1 | 2022 | 7 | 0.740 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2014 | 60 | 0.720 |
Why?
|
| Momordica charantia | 1 | 2021 | 17 | 0.700 |
Why?
|
| Receptors, CCR | 5 | 2014 | 26 | 0.700 |
Why?
|
| Chemokine CXCL13 | 6 | 2014 | 18 | 0.660 |
Why?
|
| Connaraceae | 1 | 2020 | 1 | 0.660 |
Why?
|
| Receptors, CXCR5 | 5 | 2014 | 15 | 0.660 |
Why?
|
| Inflammation | 4 | 2022 | 758 | 0.650 |
Why?
|
| Hedgehog Proteins | 1 | 2020 | 54 | 0.630 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 290 | 0.620 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 136 | 0.610 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2020 | 133 | 0.610 |
Why?
|
| Receptors, Virus | 2 | 2016 | 23 | 0.590 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 88 | 0.570 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 1723 | 0.560 |
Why?
|
| Biological Products | 1 | 2020 | 91 | 0.560 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 64 | 0.560 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 28 | 0.560 |
Why?
|
| Pneumococcal Infections | 3 | 2014 | 33 | 0.550 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 163 | 0.530 |
Why?
|
| Immunity | 1 | 2017 | 61 | 0.530 |
Why?
|
| Chemokines, CXC | 3 | 2016 | 36 | 0.520 |
Why?
|
| Folic Acid | 3 | 2023 | 49 | 0.520 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2017 | 23 | 0.520 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 56 | 0.510 |
Why?
|
| Receptors, Scavenger | 2 | 2016 | 16 | 0.510 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 224 | 0.510 |
Why?
|
| Epitope Mapping | 2 | 2014 | 32 | 0.500 |
Why?
|
| Stilbenes | 1 | 2017 | 44 | 0.500 |
Why?
|
| Female | 28 | 2024 | 24698 | 0.480 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2016 | 18 | 0.480 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 144 | 0.470 |
Why?
|
| Cytoskeleton | 1 | 2016 | 114 | 0.470 |
Why?
|
| Curcumin | 1 | 2017 | 118 | 0.460 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 218 | 0.450 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 116 | 0.450 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 220 | 0.440 |
Why?
|
| Immunodominant Epitopes | 1 | 2014 | 29 | 0.420 |
Why?
|
| Gram-Positive Bacteria | 3 | 2008 | 21 | 0.410 |
Why?
|
| Gene Regulatory Networks | 2 | 2024 | 149 | 0.410 |
Why?
|
| Neoplasm Metastasis | 3 | 2015 | 237 | 0.370 |
Why?
|
| Surface Plasmon Resonance | 2 | 2022 | 42 | 0.350 |
Why?
|
| Gram-Negative Bacteria | 2 | 2008 | 29 | 0.340 |
Why?
|
| Epitopes | 1 | 2011 | 157 | 0.340 |
Why?
|
| Male | 21 | 2020 | 23409 | 0.340 |
Why?
|
| Protein Binding | 6 | 2021 | 1082 | 0.330 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 100 | 0.330 |
Why?
|
| Cell Survival | 5 | 2025 | 945 | 0.290 |
Why?
|
| Boron Compounds | 3 | 2013 | 18 | 0.290 |
Why?
|
| Patient Admission | 2 | 2019 | 50 | 0.290 |
Why?
|
| Pancreatitis | 2 | 2019 | 21 | 0.280 |
Why?
|
| Technology, Pharmaceutical | 1 | 2008 | 35 | 0.280 |
Why?
|
| Animals | 18 | 2025 | 16992 | 0.270 |
Why?
|
| Structure-Activity Relationship | 6 | 2013 | 506 | 0.270 |
Why?
|
| Drug Carriers | 2 | 2025 | 174 | 0.260 |
Why?
|
| Peptides | 2 | 2010 | 372 | 0.260 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 495 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 652 | 0.260 |
Why?
|
| Mice, Inbred BALB C | 4 | 2014 | 694 | 0.250 |
Why?
|
| Interleukin-10 | 5 | 2015 | 87 | 0.250 |
Why?
|
| Patient Readmission | 2 | 2018 | 122 | 0.250 |
Why?
|
| Prognosis | 5 | 2024 | 861 | 0.240 |
Why?
|
| Proteins | 1 | 2008 | 382 | 0.230 |
Why?
|
| Zein | 1 | 2025 | 1 | 0.230 |
Why?
|
| Sphingomyelins | 1 | 2025 | 9 | 0.230 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 291 | 0.230 |
Why?
|
| RNA, Messenger | 4 | 2019 | 1271 | 0.220 |
Why?
|
| Mice | 13 | 2015 | 6644 | 0.220 |
Why?
|
| Signal Transduction | 7 | 2020 | 2157 | 0.210 |
Why?
|
| Quinazolines | 1 | 2004 | 38 | 0.210 |
Why?
|
| Flavonols | 1 | 2023 | 19 | 0.210 |
Why?
|
| Colitis | 4 | 2008 | 71 | 0.210 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 79 | 0.200 |
Why?
|
| Bacteria | 1 | 2006 | 293 | 0.200 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2013 | 245 | 0.200 |
Why?
|
| Cell Adhesion | 3 | 2016 | 238 | 0.200 |
Why?
|
| Paclitaxel | 1 | 2023 | 64 | 0.200 |
Why?
|
| Metalloproteases | 2 | 2015 | 18 | 0.200 |
Why?
|
| Colonic Neoplasms | 1 | 2025 | 223 | 0.190 |
Why?
|
| Receptors, CXCR3 | 5 | 2016 | 31 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 94 | 0.190 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2014 | 31 | 0.190 |
Why?
|
| Inflammation Mediators | 2 | 2022 | 140 | 0.180 |
Why?
|
| Oleanolic Acid | 1 | 2021 | 6 | 0.180 |
Why?
|
| Neoplasm Proteins | 1 | 2023 | 228 | 0.180 |
Why?
|
| Nanomedicine | 1 | 2022 | 52 | 0.180 |
Why?
|
| Prostate | 3 | 2016 | 155 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 4 | 2016 | 508 | 0.170 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2011 | 34 | 0.170 |
Why?
|
| Cell Cycle | 2 | 2020 | 346 | 0.160 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 11 | 0.160 |
Why?
|
| Flow Cytometry | 4 | 2016 | 411 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 3 | 2016 | 114 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2010 | 279 | 0.160 |
Why?
|
| Plant Leaves | 1 | 2020 | 136 | 0.160 |
Why?
|
| Binding Sites | 1 | 2021 | 671 | 0.150 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 1180 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 173 | 0.150 |
Why?
|
| Chemokine CX3CL1 | 1 | 2019 | 15 | 0.150 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 1542 | 0.150 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 60 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 704 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 183 | 0.150 |
Why?
|
| Pancreatitis, Chronic | 1 | 2018 | 6 | 0.150 |
Why?
|
| Incidence | 5 | 2020 | 1078 | 0.140 |
Why?
|
| Interferon-gamma | 4 | 2014 | 269 | 0.140 |
Why?
|
| Dendritic Cells | 3 | 2015 | 132 | 0.140 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 2 | 2008 | 6 | 0.140 |
Why?
|
| Blotting, Western | 3 | 2016 | 883 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 241 | 0.140 |
Why?
|
| Liposomes | 2 | 2009 | 132 | 0.130 |
Why?
|
| Altitude | 1 | 2017 | 10 | 0.130 |
Why?
|
| Occupational Diseases | 1 | 2017 | 53 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2018 | 128 | 0.130 |
Why?
|
| Killer Cells, Natural | 2 | 2008 | 104 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 38 | 0.130 |
Why?
|
| Immunoblotting | 1 | 2017 | 181 | 0.130 |
Why?
|
| Occupational Exposure | 1 | 2017 | 91 | 0.130 |
Why?
|
| Binding, Competitive | 3 | 2012 | 109 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2017 | 195 | 0.120 |
Why?
|
| Cell Line | 2 | 2018 | 1410 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 256 | 0.120 |
Why?
|
| Androgens | 1 | 2017 | 106 | 0.120 |
Why?
|
| Andrographis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Mice, Knockout | 4 | 2015 | 1035 | 0.120 |
Why?
|
| Military Personnel | 1 | 2017 | 110 | 0.120 |
Why?
|
| Receptors, CXCR | 1 | 2016 | 6 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2015 | 35 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 201 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 161 | 0.120 |
Why?
|
| Particle Size | 2 | 2025 | 272 | 0.120 |
Why?
|
| Spleen | 2 | 2014 | 204 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 2853 | 0.120 |
Why?
|
| Fertility | 1 | 2015 | 62 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 863 | 0.110 |
Why?
|
| Diterpenes | 1 | 2016 | 97 | 0.110 |
Why?
|
| Chlamydia muridarum | 1 | 2015 | 104 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 174 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 485 | 0.110 |
Why?
|
| Tissue Array Analysis | 2 | 2011 | 80 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2014 | 27 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2017 | 863 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 134 | 0.100 |
Why?
|
| Interleukins | 1 | 2014 | 40 | 0.100 |
Why?
|
| Coculture Techniques | 1 | 2014 | 109 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 2 | 2011 | 49 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2014 | 74 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2012 | 1869 | 0.100 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2011 | 22 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 182 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 321 | 0.100 |
Why?
|
| Chlamydia Infections | 1 | 2015 | 200 | 0.100 |
Why?
|
| Models, Molecular | 2 | 2014 | 876 | 0.100 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2013 | 2 | 0.100 |
Why?
|
| Benzoxazoles | 1 | 2013 | 10 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 249 | 0.100 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 59 | 0.100 |
Why?
|
| Protein Subunits | 1 | 2013 | 93 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 734 | 0.100 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2013 | 28 | 0.100 |
Why?
|
| Prostatic Hyperplasia | 2 | 2009 | 32 | 0.100 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2012 | 8 | 0.100 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2012 | 33 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2016 | 434 | 0.090 |
Why?
|
| Risk Factors | 5 | 2020 | 3994 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 63 | 0.090 |
Why?
|
| Pyrans | 1 | 2012 | 10 | 0.090 |
Why?
|
| Azepines | 1 | 2012 | 22 | 0.090 |
Why?
|
| Mutation | 1 | 2017 | 1177 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2012 | 95 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 18 | 0.090 |
Why?
|
| Models, Immunological | 1 | 2011 | 21 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2013 | 36 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2010 | 458 | 0.090 |
Why?
|
| Smoke | 1 | 2011 | 42 | 0.090 |
Why?
|
| Pyridines | 1 | 2012 | 139 | 0.080 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 84 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 187 | 0.080 |
Why?
|
| Antibodies, Bacterial | 2 | 2008 | 117 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2012 | 139 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 185 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2011 | 207 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 117 | 0.080 |
Why?
|
| Cisplatin | 1 | 2011 | 98 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 102 | 0.080 |
Why?
|
| Histocompatibility Antigens | 1 | 2010 | 12 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2017 | 719 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 114 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2010 | 49 | 0.080 |
Why?
|
| Escherichia coli | 1 | 2013 | 460 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 166 | 0.080 |
Why?
|
| Aged | 5 | 2020 | 8214 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2008 | 104 | 0.070 |
Why?
|
| Adult | 7 | 2020 | 13872 | 0.070 |
Why?
|
| Dendrimers | 1 | 2009 | 15 | 0.070 |
Why?
|
| Integrins | 1 | 2009 | 54 | 0.070 |
Why?
|
| Micelles | 1 | 2009 | 36 | 0.070 |
Why?
|
| DNA Damage | 1 | 2011 | 356 | 0.070 |
Why?
|
| Interleukin-1beta | 3 | 2015 | 75 | 0.070 |
Why?
|
| India | 2 | 2020 | 108 | 0.070 |
Why?
|
| Fluoroquinolones | 1 | 2008 | 9 | 0.070 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2008 | 13 | 0.070 |
Why?
|
| Absorption | 1 | 2008 | 22 | 0.070 |
Why?
|
| Quantum Dots | 1 | 2009 | 38 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2011 | 358 | 0.070 |
Why?
|
| Hydrogels | 1 | 2009 | 59 | 0.070 |
Why?
|
| Image Cytometry | 1 | 2007 | 6 | 0.070 |
Why?
|
| Drug Stability | 1 | 2008 | 129 | 0.070 |
Why?
|
| Young Adult | 4 | 2020 | 5080 | 0.070 |
Why?
|
| Chemokine CXCL10 | 1 | 2008 | 38 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 47 | 0.070 |
Why?
|
| Immunity, Mucosal | 1 | 2008 | 53 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 260 | 0.070 |
Why?
|
| Paratuberculosis | 1 | 2007 | 4 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 144 | 0.070 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 55 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2007 | 154 | 0.070 |
Why?
|
| DNA Gyrase | 1 | 2006 | 8 | 0.060 |
Why?
|
| DNA Topoisomerase IV | 1 | 2006 | 3 | 0.060 |
Why?
|
| Biocompatible Materials | 1 | 2008 | 108 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 12 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2013 | 384 | 0.060 |
Why?
|
| Polymers | 1 | 2008 | 155 | 0.060 |
Why?
|
| Middle Aged | 5 | 2020 | 12222 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2018 | 2544 | 0.060 |
Why?
|
| Amines | 1 | 2006 | 41 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2006 | 99 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 367 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2008 | 570 | 0.060 |
Why?
|
| Interleukin-6 | 3 | 2013 | 165 | 0.060 |
Why?
|
| Carrier State | 1 | 2006 | 33 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2007 | 383 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 386 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2011 | 1003 | 0.060 |
Why?
|
| HCT116 Cells | 1 | 2025 | 40 | 0.060 |
Why?
|
| Hydroxyquinolines | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2024 | 44 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 458 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1285 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2025 | 388 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2024 | 368 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 188 | 0.050 |
Why?
|
| United States | 3 | 2019 | 5205 | 0.050 |
Why?
|
| Chemokine CXCL11 | 2 | 2016 | 7 | 0.050 |
Why?
|
| Adolescent | 3 | 2019 | 6081 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 408 | 0.050 |
Why?
|
| Crystallography, X-Ray | 2 | 2013 | 280 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 247 | 0.040 |
Why?
|
| Kinetics | 2 | 2013 | 695 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 2 | 2011 | 29 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 1 | 2020 | 7 | 0.040 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2010 | 4 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 26 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 86 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 97 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 299 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 667 | 0.040 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 9 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2018 | 10 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 186 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2018 | 14 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2019 | 91 | 0.040 |
Why?
|
| Angiography | 1 | 2017 | 15 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 155 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 229 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 341 | 0.030 |
Why?
|
| Th1 Cells | 2 | 2008 | 97 | 0.030 |
Why?
|
| Logistic Models | 1 | 2010 | 1009 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 1070 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 490 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 278 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 638 | 0.030 |
Why?
|
| Cyclin B1 | 1 | 2016 | 18 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2016 | 19 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 245 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 26 | 0.030 |
Why?
|
| Cyclins | 1 | 2016 | 34 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Ligands | 2 | 2007 | 388 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 29 | 0.030 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2015 | 4 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2015 | 53 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1154 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2015 | 58 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2015 | 43 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2015 | 20 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 65 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 139 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1067 | 0.030 |
Why?
|
| Histones | 1 | 2016 | 197 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1063 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 1857 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 209 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 333 | 0.030 |
Why?
|
| Receptor, PAR-1 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Thrombin | 1 | 2013 | 28 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 34 | 0.020 |
Why?
|
| Thigh | 1 | 2013 | 12 | 0.020 |
Why?
|
| Half-Life | 1 | 2013 | 63 | 0.020 |
Why?
|
| Leucine | 1 | 2013 | 31 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2013 | 50 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 139 | 0.020 |
Why?
|
| beta-Lactamases | 1 | 2013 | 34 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 74 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 986 | 0.020 |
Why?
|
| Calcium | 1 | 2015 | 491 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1124 | 0.020 |
Why?
|
| Dibenzazepines | 1 | 2012 | 1 | 0.020 |
Why?
|
| Flurbiprofen | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2012 | 15 | 0.020 |
Why?
|
| Receptor, EphB2 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Sulindac | 1 | 2012 | 9 | 0.020 |
Why?
|
| Receptor, EphA4 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Carbamates | 1 | 2012 | 13 | 0.020 |
Why?
|
| Alanine | 1 | 2012 | 34 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2012 | 118 | 0.020 |
Why?
|
| Dipeptides | 1 | 2012 | 31 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2012 | 143 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 168 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2013 | 108 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2012 | 38 | 0.020 |
Why?
|
| Metals | 1 | 2012 | 114 | 0.020 |
Why?
|
| Piperidines | 1 | 2012 | 83 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2011 | 24 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 150 | 0.020 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2011 | 12 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 20 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 27 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 1596 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 95 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 2011 | 36 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 239 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 561 | 0.020 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 37 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2012 | 91 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 146 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 142 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 108 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 518 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 151 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 105 | 0.020 |
Why?
|
| Chemokine CXCL5 | 1 | 2010 | 5 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 198 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 712 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1081 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 13 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 55 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 462 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 934 | 0.020 |
Why?
|
| Serum Amyloid A Protein | 1 | 2008 | 14 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 374 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2009 | 114 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2007 | 35 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 147 | 0.020 |
Why?
|
| Granulocytes | 1 | 2007 | 26 | 0.020 |
Why?
|
| Cell Size | 1 | 2007 | 46 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 94 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 24 | 0.020 |
Why?
|
| Neutrophils | 1 | 2008 | 145 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 74 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 224 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 184 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 91 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2007 | 69 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 376 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 144 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 134 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 259 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 3735 | 0.010 |
Why?
|
| Brain | 1 | 2012 | 1472 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 1621 | 0.010 |
Why?
|